Done deal: The Tipline for 22 November 2019
Bristol-Myers Squibb has completed its $74 billion takeover of biotechnology company Celgene. The companies announced the deal in January and last week received conditional approval with a narrow 3-2 vote from the Federal Trade Commission. The companies agreed to the largest divestiture in US merger control history – Celgene’s sale of psoriasis drug Otezla to Amgen for $13.4 billion – to obtain FTC clearance.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is a leading global provider of competition law, regulation and enforcement information, combining data, deep market insight and a user-centric platform to provide our clients with powerful legal solutions.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10